Target Price | €30.15 |
Price | €28.75 |
Potential |
4.87%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Revenio Group 2026 .
The average Revenio Group target price is €30.15.
This is
4.87%
register free of charge
€33.50
16.52%
register free of charge
€28.00
2.61%
register free of charge
|
|
A rating was issued by 7 analysts: 5 Analysts recommend Revenio Group to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Revenio Group stock has an average upside potential 2026 of
4.87%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million € | 103.52 | 113.83 |
7.19% | 9.96% | |
EBITDA Margin | 29.21% | 30.84% |
6.86% | 6.81% | |
Net Margin | 17.99% | 19.49% |
9.30% | 8.36% |
7 Analysts have issued a sales forecast Revenio Group 2025 . The average Revenio Group sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Revenio Group EBITDA forecast 2025. The average Revenio Group EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Revenio Group Analysts have issued a net profit forecast 2025. The average Revenio Group net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share € | 0.70 | 0.83 |
2.78% | 18.57% | |
P/E | 34.47 | |
EV/Sales | 6.63 |
6 Analysts have issued a Revenio Group forecast for earnings per share. The average Revenio Group EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.